NEW YORK (GenomeWeb) – Foundation Medicine said today that is has partnered with Pfizer to develop companion diagnostics for Pfizer's oncology therapies.

The new companion diagnostics will be included in updates to FoundationOne CDx, Foundation Medicine's comprehensive genomic profiling assay for solid tumors that includes multiple companion diagnostics and which was recently approved by the US Food and Drug Administration.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.